HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
The Clinical Vector Core (CVC) is a leader in viral vector manufacturing at Children’s Hospital of Philadelphia and the University of Pennsylvania, in support of investigational new drug applications (IND) and clinical studies worldwide. Our proven success has resulted in more than 181 vector products for 37 unique clinical indications that have reached 859 patients since 2007.* Learn more about how our vector products have affected patients’ lives.
*As of Sep 2024
For best viewing capabilities, we recommend using Firefox, Chrome, Safari, or Microsoft Edge.
Key Metrics
Metrics as of Sep 2024
106
# of Study Sites
37
# of INDs
10
# of Countries
Patients & Sites
Product Distribution
Our vectors have been successful and impactful in the field of cell and gene therapy, including the first-ever gene therapies approved by the U.S. Food and Drug Administration Kymriah® (tisagenlecleucel) and Luxturna™ (voretigene neparvovec-rzyl).
The Clinical Vector Core’s team of experts supports early-phase studies with vector production that is affordable, is completed within a short timeframe, and offers flexibility — all with quality control and quality assurance compliant with current Good Manufacturing Practices (cGMP).
The Clinical Vector Core Sets the Standard
Approved supplier of GMP-process comparable pharm/tox material and investigational products for the National Institutes of Health (2021-present).
Compliant with U.S. FDA, Medicines and Healthcare Products Regulatory Agency (MHRA), and European Medicines Agency (EMA) GMP manufacturing regulations applicable to early phase clinical trials.
Suited to national and international projects from academia, industry, and government.